about
Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeuticsINTERACTING DISCIPLINES: Cardiac natriuretic peptides and obesity: perspectives from an endocrinologist and a cardiologistNeprilysin deficiency protects against fat-induced insulin secretory dysfunction by maintaining calcium influx.Obesity Accelerates Alzheimer-Related Pathology in APOE4 but not APOE3 Mice.Metabolic syndrome: definitions and controversies.Hyperinsulinemia correlates with low levels of plasma B-type natriuretic peptide in Japanese men irrespective of fat distribution.Effect of Inhibition of Angiotensin-Converting Enzyme and/or Neutral Endopeptidase on Neuropathy in High-Fat-Fed C57Bl/6J Mice.Brain-Wide Insulin Resistance, Tau Phosphorylation Changes, and Hippocampal Neprilysin and Amyloid-β Alterations in a Monkey Model of Type 1 Diabetes.Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axisDoes GLP-1 suppress its own basal secretion?Angiotensin II Receptor Blocker Neprilysin Inhibitor (ARNI): New Avenues in Cardiovascular Therapy.Neprilysin facilitates adipogenesis through potentiation of the phosphatidylinositol 3-kinase (PI3K) signaling pathway.Molecular Physiology of Membrane Guanylyl Cyclase Receptors.GLP-1 receptor independent pathways: emerging beneficial effects of GLP-1 breakdown products.Combining angiotensin II receptor 1 antagonism and neprilysin inhibition for the treatment of heart failure.In silico based investigation of dynamic variations in neprilysin (NEP and NEP2) proteins for extracting the point of specificity.Neprilysin regulates pulmonary artery smooth muscle cell phenotype through a platelet-derived growth factor receptor-dependent mechanism.NTproBNP in insulin-resistance mediated conditions: overweight/obesity, metabolic syndrome and diabetes. The population-based Casale Monferrato StudyImproved glycaemia in high-fat-fed neprilysin-deficient mice is associated with reduced DPP-4 activity and increased active GLP-1 levels.LCZ696, a promising novel agent in treating hypertension (a meta-analysis of randomized controlled trials).Natriuretic peptides in the control of lipid metabolism and insulin sensitivity.Reduction and fragmentation of elastic fibers in the skin of obese mice is associated with altered mRNA expression levels of fibrillin-1 and neprilysin.The effects of angiotensin receptor neprilysin inhibition by sacubitril/valsartan on adipose tissue transcriptome and protein expression in obese hypertensive patients.Neprilysin Deficiency Is Associated With Expansion of Islet β-Cell Mass in High Fat-Fed Mice.TLR4 inhibitor TAK-242 attenuates the adverse neural effects of diet-induced obesityMetabolic effects of sacubitril/valsartan: are they relevant in clinical practice?
P2860
Q27004000-4FC45B5D-232E-4457-88AF-86CAA269669BQ28083473-D3E00BFE-95A7-4908-862D-4863755BBA98Q30539196-42082B4B-643F-43E8-83E2-CB4577F59C90Q33791780-50154107-B991-4365-995F-A65A1586A6A9Q35047747-8C429FD2-8BF7-4AE4-A74B-E91CB0F1BDE3Q35873498-B73C3785-94C4-4C16-B1F3-C9B1443F3F6CQ36302451-F0C71F47-E8DE-4E60-9813-D608A05211FEQ36792589-FAD6A0AE-7089-4348-BDF4-061BC7BF3E6CQ37101896-9BD70225-E2D4-4281-80F3-9C17A481AAB0Q37517436-FB863BFB-3419-4A07-B524-CDCD87E25FB5Q38534772-9645C191-5AEB-4BC7-97B9-BE43498E2B45Q38714743-790D1B98-E6FB-4F85-B453-31BF8E3E3368Q38794203-90E30BD7-4CD3-4756-8A90-8BF4EB40DAB3Q39063954-27FD4560-82C2-461D-BF44-712EFFE3B45EQ40000430-70552102-C9C0-4865-AE1A-C2D7446BCBCBQ40022592-897045C1-EB0F-4D0F-B7DA-C00A58DEAC39Q41201643-459A4665-6D60-4916-A5F4-6D087BEBDB50Q42363898-E691396E-3AA9-4555-974D-A1248E2F4746Q48017526-B74D9D49-E501-4B87-8F67-4108745D8C75Q49320299-2CD2F3B1-C528-47DE-ADD0-01F2F4A58AE0Q50122007-7A8CE0E9-DB33-4E29-9C87-873A812FF1CDQ51040876-E15AACED-7378-4055-BC70-ECE16B8D4838Q52676366-BCA345A8-7970-4DA1-B008-066FB5D3A0E0Q52725755-3ECCC318-49D8-485B-AAA0-11F86AA43278Q58610974-925F5EB6-DBF9-4BD9-BD41-B99E7E703112Q58804503-F8641400-693B-4DF0-B3A8-94D057873833
P2860
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Neprilysin, obesity and the metabolic syndrome
@en
Neprilysin, obesity and the metabolic syndrome
@en-gb
Neprilysin, obesity and the metabolic syndrome
@nl
type
label
Neprilysin, obesity and the metabolic syndrome
@en
Neprilysin, obesity and the metabolic syndrome
@en-gb
Neprilysin, obesity and the metabolic syndrome
@nl
prefLabel
Neprilysin, obesity and the metabolic syndrome
@en
Neprilysin, obesity and the metabolic syndrome
@en-gb
Neprilysin, obesity and the metabolic syndrome
@nl
P2093
P2860
P356
P1476
Neprilysin, obesity and the metabolic syndrome
@en
P2093
A J Balmforth
A J Turner
A M Carter
K F Standeven
P A Cordell
P2860
P2888
P304
P356
10.1038/IJO.2010.227
P407
P577
2010-11-02T00:00:00Z
P5875
P6179
1017741949